Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension). The new authorisation has been granted for a single-dose, pre-filled pen device that requires no titration ...
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
FRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield ... receive extended-release exenatide 2 mg by subcutaneous pen injection once ...
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...
AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...
Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted ...
Study participants (n=194) were randomly assigned 1:1 to receive subcutaneous exenatide extended-release 2mg or placebo once weekly for 96 weeks. The primary endpoint was the Movement Disorder ...